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Abstract
Background: 1q21 microdeletion syndrome is a rare contiguous gene deletion disorder with de novo or autosomal
dominant inheritance patterns and its phenotypic features include intellectual disability, distinctive facial
dysmorphism, microcephaly, cardiac abnormalities, and cataracts. MECP2 duplication syndrome is an X-linked
recessive neurodevelopmental disorder characterized by intellectual disability, global developmental delay, and
other neurological complications including late-onset seizures. Previously, these two different genetic syndromes
have not been reported segregating independently in a same family.
Case presentation: Here we describe two siblings carrying either a chromosome 1q21 microdeletion or a
chromosome Xq28 duplication. Using a comparative genomic hybridization (CGH) array, we identified a 1.24 Mb
heterozygous deletion at 1q21 resulting in the loss of 9 genes in a girl with learning disability, hypothyroidism,
short stature, sensory integration disorder, and soft dysmorphic features including cupped ears and a unilateral ear
pit. We also characterized a 508 kb Xq28 duplication encompassing MECP2 in her younger brother with hypotonia,
poor speech, cognitive and motor impairment. The parental CGH and quantitative PCR (qPCR) analyses revealed
that the 1q21 deletion in the elder sister is de novo, but the Xq28 duplication in the younger brother was originally
inherited from the maternal grandmother through the mother, both of whom are asymptomatic carriers. RT-qPCR
assays revealed that the affected brother has almost double the amount of MECP2 mRNA expression compared to
other family members of both genders including maternal grandmother and mother who have the same Xq28
duplication with no phenotype. This suggests the X chromosome with an Xq28 duplication in the carrier females is
preferentially silenced.
Conclusion: From our understanding, this would be the first report showing the independent segregation of two
genetically unrelated syndromes, 1q21 microdeletion and Xq28 duplication, in a same family, especially in siblings.
Although these two chromosomal abnormalities share some similar phenotypes such as intellectual disability, mild
dysmorphic features, and cardiac abnormalities, the presence of two unrelated and rare syndromes in siblings is
very unusual. Therefore, further comprehensive investigations in similar cases are required for future studies.
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Background
The 1q21 microdeletion (MIM 612474) is a very rare
genetic disorder with the deleted region spanning from
145.4 Mb to 147.8 Mb (hg19) on chromosome 1. 1q21
microdeletion can occur de novo, but the majority of
microdeletions are inherited from either parent in an
autosomal dominant manner [1–3]. Haploinsufficiency
of the genes deleted at 1q21 likely contribute to the
clinical phenotypes associated with this microdeletion. A
parent with the same microdeletion generally shows a
normal phenotype, or very mild phenotype that is simi-
lar to or less severe than that of their child [1]. This
suggests the possibility of parental imprinting, reduced
penetrance, or variable expressivity. The phenotypic fea-
tures prompting diagnosis of 1q21 microdeletion include
mild to moderate intellectual disability, learning disability,
microcephaly, mildly dysmorphic facial features and skel-
etal malformations [1–4], cataracts [2, 5] and heart abnor-
malities [5, 6]. Because these clinical features are also seen
in other genetic disorders, 1q21 microdeletion is difficult
to be diagnosed clinically and more often molecularly di-
agnosed by chromosomal microarray analysis [1, 2, 4].
Xq28 duplication syndrome (MIM 300815) resulting
in functional disomy of Xq28 has been predominantly
described in male patients with syndromic intellectual
disability including infantile hypotonia, poor or absent
speech, and recurrent pulmonary infections [7, 8]. The
clinical features of Xq28 duplications differ, dependent
on the location and the size ranging typically from 0.3 to
2 Mb [9–12]. One of the multiple genes duplicated in
this intellectual disability syndrome is methyl CpG-
binding protein 2 (MECP2; MIM 300005), a chromo-
somal protein that binds specifically to methylated DNA
[13]. Early studies demonstrated that MECP2 represses
transcription from methylated promoters [14] and is
subject to X chromosome inactivation in both mouse
and human [15, 16]. Furthermore, MECP2 is an essential
regulator in postnatal brain development and a critical
dosage-sensitive gene involved in neurological abnormal-
ities [17, 18]. In the inherited cases, the disorder almost
exclusively affects males, and the MECP2 duplication in
a carrier mother with favorable skewing of X-
chromosome inactivation results in minimal to no clin-
ical findings [8] But rarely, females who carry the same
duplication on one X chromosome may exhibit mild to
severe clinical features seen in affected males [12, 19]. In
some cases, the duplication occurs de novo [12, 20].
Here we report two genetically unrelated rare syn-
dromes in a family. A deletion in a girl and one duplica-
tion inherited in her brother. The first chromosomal
aberration is a de novo 1q21 microdeletion involving 9
genes. The other chromosomal anomaly, Xq28 duplication
encompassing 15 genes including MECP2, is inherited
from the asymptomatic mother. We performed qPCR to
further confirm the CNVs and familial inheritance
patterns of these chromosome rearrangements, and quan-
tified the mRNA expression levels of MECP2 using RT-
qPCR. In addition, we discussed genotype-phenotype cor-
relations in patients with these two rare syndromes.
Methods
Cell culture
Lymphoblastoid cell lines (LCLs) were established from
blood samples obtained from patients and their family
members and maintained as previously described [21].
Comparative genomic hybridization (CGH) array
Genomic DNA (gDNA) was extracted from peripheral
blood lymphocytes using standard phenol/chloroform
extraction method [21]. The isolated genomic DNAs
were examined for copy number variations (CNVs) using
the Agilent 244 K Agilent comparative genomic
hybridization (CGH) array (Agilent Technologies).
Quantitative polymerase chain reaction (qPCR) for the
confirmation of deletion and duplication
Primers used for the confirmation of the 1q21 and 7q11
deletion and Xq28 duplication are listed in Table 1. A
primer set amplifying the exon 8 of GAPDH was used as
an internal control. Total 10 ng of gDNA was mixed
with Power SYBR Green PCR Master Mix (Applied
Biosystems, Carlsbad, CA) and the primers, according to
the manufacturer’s protocol. Quantitative PCR (qPCR)
was performed for the amplification of the targeted
Table 1 Primers used for qPCR in this study
Name Primer sequence (5’→ 3’)
Forward Reverse
chr1q21.1 #1 TGAGCAGTTCAAAGGAGTGTAG ATGACCCACAAAGTGAGAGAAA
chr1q21.1 #2 AAGGCTGTGAAGGAGGAAATC CTGACCAGGCAGAAGACATAAA
chr7q11 GGAGCACAAAGCAACTGAATG AGACAGCAATGCAGAGGAA
chrXq28 #1 AGAGCTCGGACTCCATCTAAT CCTTCCCATGTCAGTGTGTTAT
chrXq28 #2 CTCACTTCTGGGTCTCACATTC AATCCCAAGTGACTTCCAAGG
GAPDH GATCATCAGCAATGCCTCCT ATGGCATGGACTGTGGTCAT
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region utilizing a 7500 Real-Time PCR system (Applied
Biosystems, Carlsbad, CA). The PCR reactions were cy-
cled 40 times after initial denaturation (95 °C, 10 min)
with the following parameters: denaturation at 95 °C for
15 s; annealing at 60 °C for 1 min. The amplification
levels of GAPDH exon 8 were used to normalize relative
levels of DNA.
Reverse transcription-quantitative polymerase chain
reaction (RT-qPCR)
Total RNA was extracted from the lymphocyte cell lines
using RNeasy Mini Kit (Qiagen, Valencia, CA) according to
the instructions of the manufacturer. Total RNA 2 μg was
reverse transcribed and converted into complementary
DNA (cDNA) using the RevertAid First Strand cDNA
synthesis kit (Thermo Scientific, Waltham, MA). The fol-
lowing are primer sequences used for amplification of
MECP2 (NM_004992.3) and GAPDH (NM_002046.4);
MECP2 #1 forward 5’ – CTCAGGCCATTCCCAAGAAA
– 3’ and reverse 5’ – TCCTGCACAGATCGGATAGA – 3’;
MECP2 #2 forward 5’ – CTCTGCTGGGAAGTATGAT
GTG – 3’ reverse 5’ – TCATTAGGGTCCAGGGATGT –
3’; GAPDH forward 5’ – GATCATCAGCAATGCCTCCT
– 3’ and reverse 5’ – ATGGCATGGACTGTGGTCAT – 3’.
The cDNAs were mixed with Power SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA) and
primers. All samples and loading controls were plated in
triplicate and centrifuged briefly. RT-qPCR was performed
for the amplification of MECP2 and GAPDH utilizing a
7500 Real-Time PCR system (Applied Biosystems, Carlsbad,
CA). The PCR reactions were cycled 40 times after initial
denaturation (95 °C, 10 min) with the following parameters:
denaturation at 95 °C for 15 s; annealing at 60 °C for 1 min.
Expression of GAPDH was used to normalize relative
expression ofMECP2mRNA.
Case presentation
Our proband 1 is a 10 and half-year old Caucasian
female with learning disability, significant growth retard-
ation, microcephaly and speech delay. She was born at a
full term after a normal pregnancy and delivery with
average birth weight (3.27 kg, 50 percentile) and length
(49.5 cm, 50 percentile). No jaundice, hypotonia or
problems with feeds was observed during newborn
period. However, her weight was 25th percentile at
2 months, and less than 3rd percentile from age
8 months. Although both her weight and length has
been below 3rd percentile from age of 9 months, she has
not shown any sign of delayed milestones. At the age of
seven months, she developed oral thrush and began to
demonstrate decreased development and feeding. She
became a poor eater and tended to only drink water and
breastfeed for liquids. She had failure to thrive partly be-
cause of her swallowing problem and tongue thrust.
Since 6 months old, she continues to have constipation
with bowel movement every 3–5 days. It has not im-
proved with thyroid treatment and enema was required
at times. At 1 year and 10 months, she had laboratory
evidence of compensated hypothyroidism with normal
thyroid levels and elevated thyroid stimulating hormone,
on Synthroid treatment for symptomatic control. She
has soft dysmorphic features including cupped ears and
a unilateral ear pit in her right ear (Fig. 1a, b). Her
length was below the 3rd percentile, but her weight to
length curve was normal in the 22nd percentile (Fig. 1c).
Brain MRI, performed at 2 years and 3 months of age,
Fig. 1 Facial and whole body photographs of two affected children in our study. a, b Proband 1 at age of 4 years and 8 months has cupped ears as well
as a unilateral ear pit in her right ear. c Proband 1 at age of 4 years and 8 months shows similar length with her younger brother, proband 2 at 2 years
and 2 months. d, e Proband 2 at age of 2 years and 2 months has mild craniofacial dysmorphisms with bilateral epicanthal folds and periorbital swelling
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showed normal. She presents significant overall sensory
regulation issues. For instance, she seeks movement and
touch constantly and has inconsistent sleep patterns as
well. She demonstrates behaviors consistent with anxiety
and high arousal state. She seeks specific oral motor in-
put and prefers to have crunch and/or chewy textures.
Her behavioral studies revealed the auditory processing
concerns with difficulty processing specific directions,
which are consistent with a system that is high in
adrenaline and low in serotonin and dopamine. She has a
learning disability, struggling in math at the school, and is
seeing a speech therapist for reading difficulties. At
10.5 years of age, her cognitive function is at the level of
8.5 years.
A 244K Agilent CGH array revealed a deletion of 1q21.1-
1q21.2 spanning about 1.24 Mb of genomic DNA with the
genome coordinates from 146,542,843 to147,786,706
(GRCh37/hg19), resulting in the loss of 9 genes including
PRKAB2, FMO5, CDH1L, BCL9, ACP6, GJA5, GJA8,
GPR89B, and NBPF11 (Figs. 2a and 3a, Table 2). This
deletion has been reported to be causative for the 1q21
recurrent microdeletion syndrome [2]. The results of CGH
array in both parents demonstrated that this
del(1)(q21.1q21.2) in proband 1 occurred de novo and this
result was also confirmed by qPCR (Fig. 4a). Another
deletion identified in proband 1 was a 68 Kb deletion within
intron 2 of AUTS2 gene at 7q11.22 (Figs. 2b and 3b). The
qPCR results showed that the intronic deletion in AUTS2 in
proband 1 was inherited from the healthy father suggesting
that this deletion is a polymorphism with no clinical effect
(Fig. 4b).
Proband 2 is a 8-year old Caucasian male with
developmental delays, hypotonia, speech delay as well as
cognitive and motor impairment. He was born at full
term following a normal pregnancy, labor and delivery
with appropriate growth parameters, birth weight 3.92
Kg and length 51 cm. He remained in a hospital for
three days due to a detected ventricular septal defect
(VSD) and breathing problems. Later, he was admitted
two times at the ages of four months and then fourteen
months for enlarged heart and cyanotic changes, but
VSD subsequently closed spontaneously. At the age of
Fig. 2 The relevant section of copy number variants (CNVs) by array comparative genomic hybridization with the use of Agilent 244 K arrays. Please
note that the coordinates shown in Fig. 2 are based on NCBI36/hg18 of the Human Genome Browser, which were translated into GRCh37/hg19 in the
Case Presentation section. a 1q21 deletion in proband 1. b 7q11.22 deletion in proband 1. c Xq28 duplication in proband 2. On the scale of deviation
from the normal diploid genotype, −2 indicates a homozygous deletion, −1 indicates a haploid deletion, 0 indicates no deviation, 1 indicates a
duplication, and 2 indicates a triplication. X axis indicates the location of CNVs on chromosomes (hg18)
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eleven months, he had pressure equalization tubes and
was diagnosed with juvenile idiopathic arthritis. His
developmental delay particularly regarding his motor
milestones was observed from 6 months of age; rolling
from front to back and back to front at 3 months of age;
pulling to stand at 10 months; sitting at 11 months;
crawling in reciprocal fashion by 13 months of age and
walking with support at 20 months. However, muscle
mass, strength and muscle stretch reflexes were within
normal limits. There is no history of seizures or periodic
breathing, and no major difficulties with constipation or
teeth grinding. In the developmental test performed at
the age of 2 years, he demonstrated severe delays across
all areas consistent with overall cognitive and motor
impairment as well as craniofacial dysmorphisms with bi-
lateral epicanthal folds and periorbital swelling (Fig. 1d, e).
He had a few mild behaviors consistent with an autistic
spectrum disorder such as lack of pointing, limited play
skills and poor eye contact, but generally seems to interact
at a level consistent with his developmental level. His poor
eye contact also seems more a symptom of overall poor
attention span, and visual inattentiveness, as opposed to
lack of social awareness. He also displayed limited integra-
tion of social communication behaviors (gaze, sounds,
gestures and facial expressions) and difficulty initiating
and sustaining social interactions.
A CGH array result demonstrated that proband 2 has
508 Kb duplication at Xq28 with the genome coordi-
nates from 153,101,077 to 153,609,163 (GRCh37/hg19)
encompassing 15 genes including MECP2, one of re-
sponsible genes for Xq28 duplication syndrome (Figs. 2c
and 3c, Table 2). Parental CGH array results revealed
that this Xq28 duplication was inherited from mother.
The qPCR results using two different primers amplifying
regions within the known duplicated region revealed
that Xq28 duplication was originally inherited from ma-
ternal grandmother who inherited it to mother, a carrier
with a normal phenotype (Fig. 4c). We performed qRT-
PCR to compare the mRNA expression levels of MECP2
in proband 2 with those in other family members whose
blood samples were available. Figure 4d shows proband 2
has almost double amount of MECP2 mRNA expression
Fig. 3 Genome view of deletion and duplication regions in proband 1 (a and b) and 2 (c) exported from Human Genome Browser (Build 37/hg19).
RefSeq genes are described in http://www.genome.ucsc.edu/. Black boxes under browser maps show approximate locations of loci where primers
were designed for qPCR
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Table 2 List of affected genes in probands 1 and 2
Gene symbol Gene name OMIM # Function
Proband 1 with 1.24 Mb deletion at 1q21
PRKAB2 AMP-activated kinase complex noncatalytic beta-2 602741 Maintains systemic and cellular energy homeostasis
FMO5 Flavin-containing monooxygenase 5 603957 Involved in the metabolic activation of drugs and
xenobiotic compounds
CHD1L Chromodomain helicase DNA-binding protein 1-like 613039 Has a role in chromatin modification and DNA damage response
BCL9 B-cell CLL/lymphoma 9 602597 A signal transduction protein required for efficient beta-
catenin-mediated transcription in Wnt signaling pathway
ACP6 Acid phosphatase 6 611471 Hydrolyzes lysophosphatidic acid containing fatty acid
GJA5 Gap junction protein, alpha-5 121013 A cardiac gap junction protein connexin 40 that facilitates
cell-to-cell adhesion and intercellular communication
GJA8 Gap junction protein, alpha-8 600897 A transmembrane connexin protein that is necessary for
lens growth and maturation of lens fiber cells
GPR89B G protein-coupled receptor 89B 612806 Voltage dependent anion channel regulating the acidification
and function of Golgi apparatus
NBPF11 Neuroblastoma breakpoint family, member 11 614001 A member of the NBPF family and diseases associated with
NBPF11 include neuroblastoma
Proband 2 with 508 kb duplication at Xq28
L1CAM L1 cell adhesion molecule 308840 Belongs to immunoglobulin superfamily cell adhesion molecules
and has a role in neuronal migration and survival
AVPR2 arginine vasopressin receptor 2 300538 G protein-coupled receptor involved in the regulation of the urine
and water homeostasis in kidney
ARHGAP4 Rho GTPase activating protein 4 300023 Regulates the function of small GTP-binding proteins belonging
to the RAS superfamily
NAA10 N(alpha)-acetyltransferase 10, NatA catalytic subunit 300013 Catalytic subunit of the N-terminal acetyltransferase A complex,
which transfers an acetyl group from acetyl-coenzyme A to the
alpha-amino group on a nascent polypeptide
RENBP renin binding protein 312420 Inhibits renin by forming a dimer with renin and involved in
transport to the Golgi and synthesis of substrates in N-glycan
biosynthesis
HCFC1 host cell factor C1 300019 Involved in cell cycle regulation and functions as a transcription
repressor by inhibiting the recruitment of p300 to promoter.
Mutations of this gene cause non-syndromic X-linked intellectual
disability and X-linked cobalamin disorder.
TMEM187 transmembrane protein 187 300059 A multi-pass membrane protein, but its biological function is
not determined
IRAK1 interleukin 1 receptor associated kinase 1 300283 A putative serine/threonine kinase that plays a critical role in
immune response and become associated with the IL-1 receptor
MECP2 methyl-CpG binding protein 2 300005 Specifically binds to a single methyl-CpG pair and mediates
transcriptional repression through interaction with histone
deacetylase and a corepressor
OPN1LW opsin 1 (cone pigments), long-wave-sensitive 300822 Long-wavelength sensitive opsin, transmembrane receptor protein
with a visual pigment, which is a light-absorbing molecules that
mediate vision
OPN1MW opsin 1 (cone pigments), medium-wave-sensitive 300821 Medium-wavelength sensitive opsin, transmembrane receptor
protein with a visual pigment, which is a light-absorbing
molecules that mediate vision
TEX28 testis expressed 28 300092 A member of the red/green cone visual pigment gene family
TKTL1/TKT2 transketolase-like 1/transketolase 2 300044 A thiamine-dependent enzyme that links the pentose phosphate
pathway with the glycolytic pathway.
FLNA Filamin A 300017 An actin-binding protein involved in the reorganization of
cytoskeletion to effect in cell migration
EMD emerin 300384 A nuclear membrane protein that associates with the
nuclear membrane lamina and mediates membrane
anchorage to the cytoskeleton
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compared to other family members. However, both mater-
nal grandmother and mother have normal expression levels
ofMECP2, even though they both have same duplication.
Discussion
In this study, we report two genetically unrelated disor-
ders, 1q21 microdeletion and Xq28 duplication in sib-
lings with intellectual disability. Microarray analysis
revealed that the sister, our proband 1, carries 1.24-Mb
heterozygous deletion at 1q21.1-1q21.2 region involving
9 genes (Fig. 3a, Table 2) and a 68 Kb deletion within in-
tron 2 of AUTS2 gene at 7q11.22 (Fig. 2b). 1q21 micro-
deletion is a contiguous gene deletion syndrome caused
by the recurrent distal 1.35-Mb heterozygous deletion in
the 1q21 region and characterized by dysmorphic facial
features, mild-moderate developmental delay, intellec-
tual disability, microcephaly and short stature [1, 2, 4].
In rare cases, individuals with the deletion may have aut-
ism [22], schizophrenia [23], cataracts [2, 5] and isolated
heart defects [6]. It is also possible that apparently un-
affected patients with 1q21 deletion could have subtle
phenotypic features that are highly variable and there-
fore not easily recognizable. A previous study stated that
subtle cataracts and patent ductus arteriosus were de-
tected from one of their patients after directive studies
were performed upon discovery of the 1q21 deletion [2].
Although our proband 1 did not have cardiac anomalies
and eye problems, a lot of phenotypes detected in
proband 1 overlap the common characteristic features of
1q21 deletion syndrome such as microcephaly, develop-
mental delay, mild facial dysmorphism and short stature,
suggesting that it is likely that some of the missing genes
in chromosome 1 would be the causative genes for her
phenotypes, because the deletion in the intron 2 of
AUTS2 gene at 7q11.22 is found in her healthy father as
well as the healthy population.
Haploinsufficiency or pathogenic variants of some
genes of interest such as PRKAB2, CDH1L, BCL9, GJA5
Fig. 4 Quantitative PCR results of deletions and duplication in our family members. a qPCR results showing the 1q21 deletion using 2 different
set of primers amplifying the regions within the known deleted region in proband 1. Deletion was detected only in proband 1. A value close to
0.5 indicates deletion on one chromosome 1, but a value close 1 indicates no deletion. b qPCR results showing the 7q11 deletion in both father
and proband 1. Deletion in proband 1 was inherited from healthy father suggesting that this deletion is polymorphism. A value close to 0.5
indicates deletion on one chromosome 7, but a value close 1 indicates no deletion. c qPCR results showing duplication of Xq28 in proband 2,
mother and MGM. Xq28 duplication in proband 2 is originally inherited from the maternal grandmother. Values indicate that: 1 (no deletion on
chromosome X in male); 2 (duplication on chromosome X in male, no duplication in female); 3 (duplication on chromosome X in female). The
amplification levels of GAPDH exon 8 were used to normalize relative levels of DNA. d The mRNA expression levels of MECP2 in the family
members. Quantitative RT-PCR was performed to measure the mRNA levels of MECP2 using 2 different sets of primers specific to MECP2 mRNA
(NM_004992.3). Expression of GAPDH was used to normalize relative expression of MECP2 mRNA. Error bars represent standard errors. Proband 1: a
10-year old Caucasian female with 1q21 microdeletion; Proband 2: an 8-year old Caucasian male with Xq28 duplication; MGF: maternal grandfather;
MGM: maternal grandmother
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and GJA8 within the region of 1q21 microdeletion likely
contributes to the recognizable phenotpyes associated
with 1q21 microdeletion. PRKAB2 is a member of the
AMP kinase complex, which maintains systemic and cel-
lular energy homeostasis [24], while CHD1L is an en-
zyme with a role in chromatin modification and DNA
damage response [25]. The protein levels of both
PRKAB2 and CHD1L were decreased in lymphoblastoid
cell lines from persons with 1q21 deletion and AMP kin-
ase function in those LCLs was highly attenuated [26].
In addition, LCLs showed significant reduction in DNA
damage repair following treatment with a topoisomerase
II inhibitor [26]. These results would support the patho-
logical roles for PRKAB2 and CDH1L in 1q21 microdele-
tion. Furthermore, the fact that PRKAB2 is highly
expressed in skeletal muscle [27] may explain the short
stature and skeletal malformations in patients with 1q21
microdeletion as well as our proband 1. BCL9 is re-
quired for efficient beta-catenin-mediated transcription
in Wnt signaling pathway [28], influencing neuroplasti-
city, adult neurogenesis and mental disorders [29–31].
Therefore, BCL9 may have contributed to phenotypes
including neurological defects and mild intellectual dis-
ability in 1q21 microdeletion. Two different gap junction
proteins, GJA5 and GJA8 are also associated with
phenotypic features in patients with 1q21 microdeletion.
GJA5 and GJA8 encode for the cardiac gap junction pro-
tein connexin 40 [32] and a transmembrane connexin
protein that is necessary for lens growth and maturation
of lens fiber cells [33], respectively. Although our pro-
band 1 has neither cardiac abnormalities nor cataract, in
many different cases, the phenotypes related with muta-
tions in these two genes have already been reported.
GJA5 is thought to be a susceptibility gene for cardiac
abnormalities, because one heterozygous nonsense mu-
tation and three missense mutations segregating with
this phenotype were found in one and three unrelated
families, respectively [34, 35]. Mutations in the GJA8
gene have been found to cause several types of auto-
somal dominant cataract [36], which have been de-
scribed as congenital nuclear [37], nuclear pulverulent
[38], zonular pulverulent [39], stellate nuclear [39] and
posterior subcapsular [40]. Therefore, the most common
clinical features of 1q21 microdeletion would have been
associated with haploinsufficiency of multiple genes lo-
cated in the deleted region.
We also describe another individual in the same fam-
ily, who carries duplication in Xq28 region involving 15
genes and including MECP2 gene that has been associ-
ated with Rett syndrome (Fig. 3c, Table 2). Unlike
MECP2 duplication syndrome, Rett syndrome is caused
by the pathogenic MECP2 variants such as missense mu-
tations and intragenic rearrangements of MECP2 gene.
The pathogenic variants of MECP2 gene were detected
in approximately 80 % of individuals with classic Rett
syndrome [41–43] and 40 % of individuals with atypical
Rett syndrome [41, 42, 44]. Our proband 2 does not
meet clinical criteria for Rett syndrome, but does reflect
the clinical features described previously in males with
duplication of MECP2 [45–47]. Among the criteria for
the diagnosis of Rett syndrome [48], he only meets evi-
dence of an acquired deceleration in head growth and
absent gait. He has lost no skills but is delayed in com-
munication and fine motor skills as well. Among the
supportive criteria [48], he has had some falloff in linear
growth over the last several months, but otherwise ful-
fills none of these.
Autism like phenotypes are reported in some cases
with Xq28 duplication syndrome [49, 50], and it is very
hard to distinguish between Xq28 duplication syndrome
and autism, especially children in very young age. Our
proband 2, an 8-year old boy, also has a social commu-
nication delay and reciprocal behaviors including lack of
response to contextual cues, lack of showing and sharing
interest, lack of communicative vocalizations with con-
sonant, and repetitive movements with object and body
associated with the criteria for autism spectrum disorder
[49]. However, the pattern of delays is inconsistent with
an autistic spectrum disorder, and his social skills are
commensurate with his language and cognitive develop-
ment whereas autism typically results in more severely
delayed social skills versus other areas of development.
Although his pattern of behaviors may be characteristic
of autism spectrum disorder, it is felt that these behav-
iors reflect his significant developmental delay and that
these characteristics are better accounted for by his de-
velopmental delays associated with MECP2 duplication
syndrome.
The MECP2 gene encodes for MECP2, a chromatin-
associated protein that regulates transcription of genes
[13, 14]. It is required for maturation of neurons [51]
and critical for normal brain function [18]. The presence
of an extra copy of the MECP2 gene is believed to im-
properly regulate the expression of other genes and this
misregulation of gene expression in the brain results in
abnormal neuronal function [17, 18], leading to the signs
and symptoms of MECP2 duplication syndrome. Indeed,
mild overexpression of Mecp2 in mice causes a progres-
sive neurological disorder including seizures, spasticity
and akinesis [17, 52], that are frequently observed in in-
dividuals with Xq28 duplication. In addition to MECP2,
this duplication encompassed several other genes of inter-
est including L1CAM, FLNA and HCFC1 that previously
reported in other patients with a Xq28 duplication.
L1CAM, a cell-to-cell adhesion molecule, is primarily
found in the nervous system and functions in neuronal
cell migration and survival [53]. Mutations in L1CAM
gene are responsible for an X-linked recessive neurological
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disorder that has been described as X-linked hydroceph-
alus [54], MASA syndrome [55] or spastic paraplegia type
I (SPG1) [56]. FLNA encodes filamin A, an actin-binding
protein involved in the reorganization of cytoskeletion to
effect in cell migration [57]. Mutations in the X-linked
FLNA gene can cause the multiple malformation [58] and
neurologic disorder periventricular heterotopia mediated
by a failure in neuronal migration into the cerebral cortex
[57]. Mutations in the HCFC1 gene have been found in
males with X-linked cobalamin disorder characterized by
severe neurological symptoms including intractable epi-
lepsy, seizures and profound development delay, along
with variable biochemical manifestations [59]. Another
mutation in the 5’ UTR region of the HCFC1 gene that
leads to overexpression of HCFC1 was identified in af-
fected members of a family with X-linked intellectual dis-
ability (MRX3, MIM 309541) [60], suggesting that HCFC1
gene may be responsible for some phenotypes, especially
intellectual disability, in Xq28 duplication.
Xq28 duplication syndrome predominantly affects males
and in most cases, it is inherited from a carrier mother, who
has favorable skewing of X chromosome inactivation and no
symptoms [8]. Using qPCR analysis, the screening of familial
inheritance in our study demonstrated that Xq28 duplica-
tion in proband 2 was passed down through his mother and
maternal grandmother, a carrier with a normal phenotype
(Fig. 4c). The RT-qPCR analysis ofMECP2 expression levels
revealed that proband 2 has almost double amount of
MECP2 mRNA expression compared to other family mem-
bers including maternal grandmother and mother who have
the same MECP2 duplication, further suggesting that the
skewed inactivation of X chromosome withMECP2 duplica-
tion in two female carriers. This suggests thatMECP2 dupli-
cated on the inactive X chromosome in the asymptomatic
carrier females is completely silenced without escaping in-
activation. Given that both microdeletion and microduplica-
tion of Xq28 encompassing MECP2 cause common
phenotypic features such as intellectual disability, in-
fantile hypotonia, absent speech and developmental
regression [18, 45, 47, 61], the dosage of MECP2 is
likely stringently regulated, because both decreased and
increased amount of MECP2 cause distinct clinical pheno-
types. Importantly, proband 2’s maternal uncle who died
at 11 years old in a drowning accident had significant in-
tellectual disability and similar phenotypes with proband
2, indicating that maternal uncle was likely affected with
the same Xq28 duplication detected in his mother and sis-
ter as well as proband 2. Pedigree analysis indicates X-
linked recessive inheritance of Xq28 duplication (Fig. 5).
Although patients with 1q21 deletion and MECP2 du-
plication syndromes share some phenotypes such as
mild dysmorphic features, cardiac abnormalities and
mental retardation, it has not been reported for these
two genetically unrelated syndromes to occur in the
same family, especially in siblings like our case. There-
fore, the presence of two seemingly unrelated and rare
chromosome abnormalities in siblings is provocative,
unusual and calls for further investigations.
Conclusions
In conclusion, we report on two siblings with genetic-
ally unrelated rare syndromes, 1q21 microdeletion or
Xq28 duplication. The results of parental CGH and
qPCR analyses reveal that the 1q21 microdeletion in
the elder sister is de novo, and the Xq28 duplication
in the younger brother is inherited from the maternal
grandmother through the mother. RT-qPCR results
revealed that the affected brother has almost double
the amount of MECP2 mRNA expression compared
to other family members, including the maternal
grandmother and mother with no phenotypes. This
indicates the favorable skewing of X-chromosome
inactivation in female carriers. Given that the segrega-
tion of two rare genetic syndromes in siblings is very
unusual, our report draws an attention to the pres-
ence of two genetically unrelated syndromes in a
same family and further investigations in similar cases
would be highly informative for future studies.
Fig. 5 Pedigree of three generations showing the inheritance of
1q21 deletion and Xq28 duplication in the family. 1q21 deletion in
proband 1 occurred de novo and Xq28 duplication in proband 2 was
originally inherited from the maternal grandmother, a carrier who
inherited it to his mother, a carrier. The maternal uncle who died at
11 years old from an accident also suffered from a similar
phenotype as his nephew. This indicates that the uncle and the
nephew might have had the same Xq28 duplication
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